Ergoloid mesylate

Revision as of 20:42, 28 April 2015 by Rabin Bista (talk | contribs)
Jump to navigation Jump to search

Ergoloid mesylate
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Ergoloid mesylate is a Central Nervous System Agent that is FDA approved for the treatment of Alzheimer's disease - dementia. Common adverse reactions include nausea and gastric disturbances.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia).

Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS).

The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time.

The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status.

Dosage

1 mg three times a day.

Alleviation of symptoms is usually gradual and results may not be observed for 3–4 weeks.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ergoloid mesylate in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ergoloid mesylate in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Ergoloid mesylate in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ergoloid mesylate in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ergoloid mesylate in pediatric patients.

Contraindications

  • Ergoloid mesylates preparations are contraindicated in individuals who have previously shown hypersensitivity to the drug. Ergoloid mesylates preparations are also contraindicated in patients who have psychosis, acute or chronic, regardless of etiology.

Warnings

Precautions

  • Practitioners are advised that because the target symptoms are of unknown etiology, careful diagnosis should be attempted before prescribing ergoloid mesylates preparations.

Adverse Reactions

Clinical Trials Experience

Ergoloid mesylates preparations have not been found to produce serious side effects. Transient nausea and gastric disturbances have been reported. Ergoloid mesylates preparations do not possess the vasoconstrictor properties of the natural ergot alkaloids.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Ergoloid mesylate in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

There is limited information regarding Ergoloid mesylate Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ergoloid mesylate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Ergoloid mesylate during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Ergoloid mesylate with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Ergoloid mesylate with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Ergoloid mesylate with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Ergoloid mesylate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Ergoloid mesylate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Ergoloid mesylate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Ergoloid mesylate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Ergoloid mesylate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Ergoloid mesylate in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral

Monitoring

There is limited information regarding Monitoring of Ergoloid mesylate in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Ergoloid mesylate in the drug label.

Overdosage

There is limited information regarding Overdose of Ergoloid mesylate in the drug label.

Pharmacology

There is limited information regarding Ergoloid mesylate Pharmacology in the drug label.

Mechanism of Action

Structure

File:Ergoloid mesylate01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Ergoloid mesylate in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Ergoloid mesylate in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Ergoloid mesylate in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Ergoloid mesylate in the drug label.

How Supplied

Storage

There is limited information regarding Ergoloid mesylate Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Ergoloid mesylate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Ergoloid mesylate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Ergoloid mesylate in the drug label.

Precautions with Alcohol

  • Alcohol-Ergoloid mesylate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. Empty citation (help)
  2. "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Ergoloid mesylate
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Ergoloid mesylate
 |Label Name=Ergoloid mesylate11.png

}}

{{#subobject:

 |Label Page=Ergoloid mesylate
 |Label Name=Ergoloid mesylate11.png

}}